Compass Therapeutics Inc.

NASDAQ:CMPXUnited States

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.

Contact Information

Headquarters

80 Guest StreetBOSTON, MA, United States 02135

Phone

617-500-8099

Fax

302-655-5049

Executives

Independent Chairman of the Board

Carl Gordon

Vice Chairman of the Board and President of Research and Development

Thomas Schuetz

Independent Director

James Boylan

Independent Director

Ellen Chiniara

Independent Director

Philip Ferneau